Hepatitis drugs and vaccines market will reach $15.25bn in 2017, with further growth to 2023

Wednesday 31 July 2013, Amsterdam

This new report  predicts the world market for hepatitis treatments and vaccines will reach $15.25bn in 2017. The industry generated $8.70bn in 2012, and its revenues will show strong growth to 2023. That sales forecast and others appear in Hepatitis Drugs and Vaccines: World Market 2013-2023, published in June 2013.

That analysis shows oral antivirals – available for hepatitis B and C – dominated the industry in 2012. That drug submarket is expected to maintain its dominance in the overall hepatitis treatment and vaccines market to 2023. However, patent expiries of leading drugs, such as Baraclude, will slow overall growth of the market, as generic competitors will be launched. In spite of that trend, oral antivirals will continue to dominate the overall hepatitis treatment market owing to high demand in developing countries, where hepatitis prevalence is high.

Our study concludes that an increase in disease awareness and screening at-risk populations will also stimulate growth of the hepatitis treatment and vaccines market. This expands the treatment population and targets undiagnosed patients who are asymptomatic. Identifying these patients allows treatment to be initiated early, before the disease progresses and becomes chronic. The vaccines submarket is expected to grow as a result of wider vaccination programmes, especially in emerging countries. These regions previously have suffered from a lack of vaccination owing to low awareness and high costs. However, with the decline in vaccine prices in recent years, visiongain expects demand to rise, as more countries adopt widespread immunisation programmes to address the growing needs.

Hemant Mistry, a pharmaceutical industry analyst, said: “There will be increased focus from pharma companies to develop highly-effective hepatitis treatments to meet patient demand. This includes biosimilar interferons and direct-acting antivirals. One such area is to develop oral, interferon-free drug regimes, which offer patients convenience in dosing and reduced risk of side effects. Furthermore in emerging markets, such as China and India – where a greater population of the infected population reside – economic growth has led to growth in the middle class population, allowing medications to be more affordable.

“The hepatitis drug market also has a strong R&D pipeline, with many drugs expected to be launched during the next 10 years. In 2012, the market was dominated by companies such as Roche, and Merck & Co. However, we expect more partnerships and collaborations involving smaller companies, for established pharma companies to solidify their presence in the presence in the industry, while allowing smaller companies to penetrate this rapidly expanding market.”

This report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It forecasts these world-level submarkets:

• Oral antivirals
• Interferons
• Vaccines
• Other agents.

The investigation predicts revenues of 10 leading drugs to 2023, including Baraclude, Zeffix, Hepsera, Viread and Tyzeka. Research, data and analyses cover activities of Roche, GSK, BMS, Merck & Co., Vertex Pharmaceuticals, Gilead Sciences, Novartis and other pharmaceutical companies.

That new study also discusses R&D and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC).